Recombinant VZV Glycoprotein E (gE), Flag Tag

Varicella-zoster virus (VZV) is a highly contagious α-herpes virus that infects only humans in nature [1]. Primary VZV infection usually occurs in early childhood, causes chickenpox, and forms a lifelong latent infection in neurons in the trigeminal ganglia and dorsal root ganglia [2], while in adulthood it is prone to shingles [3]. VZV is prevalent worldwide, but there is some variation in incidence between temperate and most tropical regions. Clinical infection with VZV not only causes varicella or shingles, but also may lead to many complications such as stromal stromal keratitis and cerebrovascular stroke [1], and even life-threatening in severe cases.

VZV is an elliptical particle with a diameter of about 150 ~ 200nm, and the genome is enclosed by a 20-hedral nucleocapsid. The VZV gene is a linear double-stranded DNA molecule approximately 125,000 bp in length that encodes at least 71 open reading frames (ORFs) and associated promoter sequences [4].。 The VZV nucleocapsid is composed of 162 shell particles with a lipoprotein envelope outside the shell, and a total of 9 glycoproteins on the envelope, namely gE, gI, gC, gH, gL, gB, gK, gM and gN. Among them, gE is encoded by ORF68, the main viral structural protein, a key protein for VZV replication and viral assembly, responsible for mediating the transmission of the virus between cells; gI is encoded by ORF67 and is usually used as a chaperone protein for gE in heterodimeric gE/gI complexes, present in infected cells [5].

This product is a high-purity gE recombinant protein that carries a Flag tag at the C-terminal and has a molecular weight of 60.2 kDa. Due to glycosylation effects, this protein migrates to 54-69 kDa under non-reducing (NR) conditions (SDS-PAGE). More detailed parameters of Recombinant VZV Glycoprotein E (gE), Flag Tag are shown in Table 1.

Table 1 Detailed parameters of Recombinant VZV Glycoprotein E (gE), Flag Tag.

Reference：

[1] Laing K，Ouwendijk W J D，Koelle D M，et al. Immunobiology of Varicella-Zoster Virus Infection[J]. J Infect Dis Med，2018：218

[2] Gershon A A，Breuer J，Cohen J I，et al. Varicella zoster virus infection[J]. Nat Rev Dis Primers，2015：15-16

[3] Gabutti G，Bolognesi N，Sandri F，et al. Varicella zoster virus vaccines：an update[J]. Immunotargets Ther. 2019；8：15-28

[4] Daniel D，Tomohiko S，Werner O. Molecular Aspects of Varicella-Zoster Virus Latency[J]. Viruses，2018；10（7）：349

[5] Grose C. The Predominant Varicella- zoster Virus gE and gI Glycoprotein Complex[M]// Structure- Function Relationships of Human Pathogenic Viruses. Springer US，2002